Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Flotation

Vir Bio rides to $143m in IPO
SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.
BioNTech binds itself to public markets
The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.
Aprea closes $97.8m IPO
The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.
Viela Bio peels off $150m in IPO
AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.
Aprea collects $85m in IPO proceeds
Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
Frequency attracts $84m in IPO
The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.
Peloton pulls itself to billion-dollar IPO
Comcast NBCUniversal and Grace Beauty scored exits as Peloton Interactive floated at the top of its range to raise $1.16bn, getting a further $100m in a private placement.
Henlius hails $410m IPO
Fosun-backed Shanghai Henlius Biotech has priced shares at the bottom of its range to raise $410m in its initial public offering ahead of public trading next week.

Other News

IGM implements $175m IPO
Haldor Topsøe remains the largest shareholder of cancer treatment developer IGM Biosciences, whose shares have risen more than 50% since it floated yesterday.
Digital health comes of age in IPO surge
The developing digital health sector has had to wait almost three years for the public markets to open up to it, but when they did, it was corporate venturing portfolio companies that were first through the flotation exit doors.
SpringWorks leaps on to stock market
Pfizer spinoff Springworks, which also counts GlaxoSmithKline as an investor, secured $162m in an initial public offering that followed $228m of funding.
Cloudflare clocks up $525m in IPO
Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.
Satsuma avoids IPO headache to go public
Shin Nippon's migraine treatment spinoff, Satsuma Pharmaceuticals, floated above its range to raise $82.5m in an offering that follows $86m of funding.
10x floats in enlarged $390m IPO
The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

Editor's Picks

Peloton pulls itself to billion-dollar IPO
Comcast NBCUniversal and Grace Beauty scored exits as Peloton Interactive floated at the top of its range to raise $1.16bn, getting a further $100m in a private placement.
Cloudflare clocks up $525m in IPO
Alphabet, Baidu, Microsoft and Qualcomm all notched up exits as the cloud services provider floated above a range that had already been increased.
BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Slack slides into public markets
The SoftBank, Comcast and Alphabet-backed communication platform developer saw its shares pop and its market cap climb nearly 50% to $19.5bn following its direct listing.
test reg

Login